Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

The majority of patients with chronic myeloid leukemia are successfully managed with life-long treatment with tyrosine kinase inhibitors. In patients in chronic phase, other malignancies are among the most common causes of death, raising concerns on the relationship between these deaths and the off-...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Haematologica
Main Authors: Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Albano, Francesco, Iurlo, Alessandra, Intermesoli, Tamara, Abruzzese, Elisabetta, Levato, Luciano, D’Adda, Mariella, Pregno, Patrizia, Cavazzini, Francesco, Stagno, Fabio, Martino, Bruno, La Barba, Gaetano, Sorà, Federica, Tiribelli, Mario, Bigazzi, Catia, Binotto, Gianni, Bonifacio, Massimiliano, Caracciolo, Clementina, Soverini, Simona, Foà, Robin, Cavo, Michele, Martinelli, Giovanni, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, Rosti, Gianantonio
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685244/
https://ncbi.nlm.nih.gov/pubmed/28572163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.169532
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים